3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
3
Sarcoma
1
Lymphoid
1
Genitourinary
1
Conditions
Sarcoma
2
Wilms Tumor
1
Triple Negative Breast Neoplasms
1
Sarcoma, Synovial
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Recurrence
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Osteosarcoma
1
Neuroectodermal Tumors, Primitive
1
Neuroblastoma
1
Neoplasms, Neuroepithelial
1
Neoplasms
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Hodgkin Disease
1
Gliosarcoma
1
Glioma
1
Glioblastoma
1
Esophageal Neoplasms
1
Ependymoma
1
Diffuse Intrinsic Pontine Glioma
1
Desmoplastic Small Round Cell Tumor
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Temozolomide
51
Bevacizumab
23
Radiotherapy
16
Magnetic Resonance Spectroscopy
16
Irinotecan
15
Carmustine
12
Erlotinib Hydrochloride
10
Carboplatin
8
Surgical Procedures, Operative
6
O(6)-benzylguanine
6
Imatinib Mesylate
6
Filgrastim
6
Cyclophosphamide
6
Biopsy
6
sargramostim
5
aldesleukin
5
X-Rays
5
Thalidomide
5
Phantoms, Imaging
5
Chemotherapy, Adjuvant
5
2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole
5
temsirolimus
4
Topotecan
4
Specimen Handling
4
Sirolimus
4
Radiation
4
Peripheral Blood Stem Cell Transplantation
4
Nuclear Medicine Department, Hospital
4
Etoposide
4
Cisplatin
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Glioma
×
CLR1404
×
Sarcoma
×
Clear all
NCT03478462
2026-03-18
CLOVER-2
Cellectar Biosciences, Inc.
Phase 1
Active not recruiting
30 enrolled